After scrambling to fill global orders for its monkeypox vaccine, Bavarian Nordic raked in $1 billion in its third quarter — more than twice its revenue in the same period last year, which was $449 million.
The Denmark-based pharmaceutical company said the "all-time high revenues" were largely because of its product sales. So far this year, more than 1 million people have received its Jynneos vaccine — the only approved monkeypox vaccine in the world — and Bavarian Nordic is working on "significant orders" for 2023.
In the first nine months of 2022, the drugmaker has made $1.86 billion in revenue, which is up 37 percent from last year's figures.